Hoth Therapeutics, Inc. (NASDAQ:HOTH) Short Interest Update

Hoth Therapeutics, Inc. (NASDAQ:HOTHGet Rating) was the target of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 1,590,000 shares, a growth of 382.1% from the March 31st total of 329,800 shares. Based on an average trading volume of 3,930,000 shares, the days-to-cover ratio is presently 0.4 days.

HOTH traded down $0.02 during trading on Wednesday, reaching $0.56. The company had a trading volume of 60,105 shares, compared to its average volume of 7,093,888. Hoth Therapeutics has a 12 month low of $0.48 and a 12 month high of $2.20. The business’s fifty day moving average price is $0.64 and its 200 day moving average price is $0.78. The company has a market cap of $17.88 million, a P/E ratio of -1.03 and a beta of 1.02.

Separately, Zacks Investment Research lowered shares of Hoth Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, January 20th.

A number of institutional investors and hedge funds have recently made changes to their positions in HOTH. Goldman Sachs Group Inc. bought a new position in Hoth Therapeutics in the second quarter valued at approximately $60,000. Geode Capital Management LLC lifted its stake in Hoth Therapeutics by 51.3% in the third quarter. Geode Capital Management LLC now owns 120,361 shares of the company’s stock valued at $143,000 after buying an additional 40,790 shares in the last quarter. Bank of New York Mellon Corp bought a new position in Hoth Therapeutics in the third quarter valued at approximately $46,000. Finally, Renaissance Technologies LLC bought a new position in Hoth Therapeutics in the fourth quarter valued at approximately $110,000. 6.06% of the stock is currently owned by hedge funds and other institutional investors.

Hoth Therapeutics Company Profile (Get Rating)

Hoth Therapeutics, Inc, a biopharmaceutical company, focuses on developing therapies for dermatological disorders. The company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. Its pipeline portfolio includes HT-001, a topical formulation for the treatment of mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy; HT-002 to treat illness associated with SARS-CoV-2 infection; HT-003D for the topical treatment in acne and psoriasis applications; HT-003IB to treat inflammatory bowel diseases; HT-004 for the treatment of asthma, atopic dermatitis, and other allergic diseases; HT-005 Z-PODS to treat cutaneous lupus erythematosus; HT-006 for treatment of multiple bacterial pathogens.

Featured Articles

Receive News & Ratings for Hoth Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hoth Therapeutics and related companies with's FREE daily email newsletter.